Hepatic carcinoma-associated fibroblasts induce ido-producing regulatory dendritic cells through il-6-mediated stat3 activation

Oncogenesis

Volumn 5, Issue 2, 2016, Pages

  Cheng, J T ^a,b   Deng, Y N ^a,b   Yi, H M ^a,b   Wang, G Y ^a   Fu, B S ^a   Chen, W J ^a   Liu, W ^b   Tai, Y ^b   Peng, Y W ^a   Zhang, Q ^a,b  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b Guangdong Provincial Key Laboratory of Liver Disease Research   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85061900977     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2016.7     Document Type: Article

References (40)

1. Jia CC, Wang TT, Liu W, Fu BS, Hua X, Wang GY et al. Cancer-associated fibroblasts from hepatocellular carcinoma promote malignant cell proliferation by HGF secretion. PLoS ONE 2013; 8: e63243.
2. Erez N, Truitt M, Olson P, Arron ST, Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an nf-kappab-dependent manner. Cancer Cell 2010; 17: 135–147.
3. Hwang RF, Moore T, Arumugam T, Ramachandran V, Amos KD, Rivera A et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008; 68: 918–926.
4. Li T, Yang Y, Hua X, Wang G, Liu W, Jia C et al. Hepatocellular carcinomaassociated fibroblasts trigger NK cell dysfunction via PGE2 and IDO. Cancer Lett 2012; 318: 154–161.
5. Hembruff SL, Jokar I, Yang L, Cheng N. Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and-independent mechanisms. Neoplasia 2010; 12: 425–433.
6. Augsten M, Hägglöf C, Olsson E, Stolz C, Tsagozis P, Levchenko T et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA 2009; 106: 3414–3419.
7. Kobayashi N, Miyoshi S, Mikami T, Koyama H, Kitazawa M, Takeoka M et al. Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res 2010; 70: 7073–7083.
8. Su X, Ye J, Hsueh EC, Zhang Y, Hoft DF, Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 2010; 184: 1630–1641.
9. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31: 220–227.
10. Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ Jr, Yokota SJ, Bankert RB. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol 2007; 178: 5552–5562.
11. Ninomiya T, Akbar SM, Masumoto T, Horiike N, Onji M. Dendritic cells with immature phenotype and defective function in the peripheral blood from patients with hepatocellular carcinoma. J Hepatol 1999; 31: 323–331.
12. Maecker B, Mougiakakos D, Zimmermann M, Behrens M, Hollander S, Schrauder A et al. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia 2006; 20: 645–649.
13. Wojas K, Tabarkiewicz J, Jankiewicz M, Roliński J. Dendritic cells in peripheral blood of patients with breast and lung cancer--a pilot study. Folia Histochem Cytobiol 2004; 42: 45–48.
14. Bellik L, Gerlini G, Parenti A, Ledda F, Pimpinelli N, Neri B et al. Role of conventional treatments on circulating and monocyte-derived dendritic cells in colorectal cancer. Clin Immunol 2006; 121: 74–80.
15. Han Y, Chen Z, Yang Y, Jiang Z, Gu Y, Liu Y et al. Human CD14+CTLA-4+ regulatory dendritic cells suppress T cell response via CTLA-4-dependent IL-10 and IDO production in hepatocellular carcinoma. Hepatology 2014; 59: 567–579.
16. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 1997; 73: 309–316.
17. Dumitriu IE, Dunbar DR, Howie SE, Sethi T, Gregory CD. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 2009; 182: 2795–2807.
18. Kim R, Emi M, Tanabe K. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin Exp Immunol 2006; 146: 189–196.
19. Ghiringhelli F, Puig PE, Roux S, Parcellier A, Schmitt E, Solary E et al. Tumor cells convert immature myeloid dendritic cells into tgf-beta secreting cells inducing cd4+cd25+ regulatory t cell proliferation. J Exp Med 2005; 202: 919–929.
20. Zhao ZG, Xu W, Sun L, Li WM, Li QB, Zou P. The characteristics and immunoregulatory functions of regulatory dendritic cells induced by mesenchymal stem cells derived from bone marrow of patient with chronic myeloid leukaemia. Eur J Cancer 2012; 48: 1884–1895.
21. Huang H, Dawicki W, Zhang X, Town J, Gordon JR. Tolerogenic dendritic cells induce cd4+cd25hifoxp3+ regulatory t cell differentiation from cd4+cd25-/ lofoxp3-effector T cells. J Immunol 2010; 185: 5003–5010.
22. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762–774.
23. Sun Y, Chin YE, Weisiger E, Malter C, Tawara I, Toubai T et al. Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol 2009; 182: 5899–5903.
24. Sumpter TL, Dangi A, Matta BM, Huang C, Stolz DB, Vodovotz Y et al. Hepatic stellate cells undermine the allostimulatory function of liver myeloid dendritic cells via STAT3-dependent induction of IDO. J Immunol 2012; 189: 3848–3858.
25. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of t cell proliferation. J Immunol 2000; 164: 3596–3599.
26. Suciu-Foca N, Berloco P, Cortesini R. Tolerogenic dendritic cells in cancer, transplantation, and autoimmune diseases. Hum Immunol 2009; 70: 277–280.
27. Johnson TS, Munn DH. Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest 2012; 41: 765–797.
28. Mellor AL, Keskin DB, Johnson T, Chandler P, Munn DH. Cells expressing indoleamine 2,3-dioxygenase inhibit t cell responses. J Immunol 2002; 168: 3771–3776.
29. Popov A, Abdullah Z, Wickenhauser C, Saric T, Driesen J, Hanisch FG et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following listeria monocytogenes infection. J Clin Invest 2006; 116: 3160–3170.
30. Farias AS, Spagnol GS, Bordeaux-Rego P, Oliveira CO, Fontana AG, de Paula RF et al. Vitamin d3 induces ido(+) tolerogenic dcs and enhances treg, reducing the severity of eae. CNS Neurosci Ther 2013; 19: 269–277.
31. Lanzinger M, Jurgens B, Hainz U, Dillinger B, Raberger J, Fuchs D et al. Ambivalent effects of dendritic cells displaying prostaglandin e2-induced indoleamine 2,3-dioxygenase. Eur J Immunol 2012; 42: 1117–1128.
32. Darnell JE. Validating Stat3 in cancer therapy. Nat Med 2005; 11: 595–596.
33. Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E, Hipkiss EL et al. Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007; 179: 4313–4317.
34. Zorn E, Nelson EA, Mohseni M, Porcheray F, Kim H, Litsa D et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 2006; 108: 1571–1579.
35. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009; 15: 114–123.
36. Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J et al. A critical role for Stat3 signaling in immune tolerance. Immunity 2003; 19: 425–436.
37. Nefedova Y, Nagaraj S, Rosenbauer A, Muro-Cacho C, Sebti SM, Gabrilovich DI. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res 2005; 65: 9525–9535.
38. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005; 11: 1314–1321.
39. Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol 2007; 178: 6867–6875.
40. Deng Y, Yi S, Wang G, Cheng J, Zhang Y, Chen W et al. Umbilical cord-derived mesenchymal stem cells instruct dendritic cells to acquire tolerogenic phenotypes through the IL-6-mediated upregulation of SOCS1. Stem Cells Dev 2014; 23: 2080–2092.